- Home
- MRK
as of 12-03-2025 11:51am EST
$102.51
+$1.43
+1.41%
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Chart Type:
Time Range:
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | RAHWAY |
| Market Cap: | 260.2B | IPO Year: | N/A |
| Target Price: | $109.64 | AVG Volume (30 days): | 14.9M |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 7.56 | EPS Growth: | 58.08 |
| 52 Week Low/High: | $73.31 - $105.84 | Next Earning Date: | 10-30-2025 |
| Revenue: | $64,235,000,000 | Revenue Growth: | 1.68% |
| Revenue Growth (this year): | 1.97% | Revenue Growth (next year): | 4.96% |
AI-Powered MRK Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 17 hours ago
AI Recommendation
hold
Model Accuracy: 75.32%
75.32%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Merck & Company Inc. (new) (MRK)
Downing Cristal N
Sell
Chief Comm. & Public Afrs Ofcr
MRK Nov 10, 2025
Avg Cost/Share
$87.00
Shares
7,085
Total Value
$616,395.00
Owned After
0
SEC Form 4
Williams David Michael
Sell
EVP,Chief Info&Digital Officer
MRK Nov 3, 2025
Avg Cost/Share
$83.59
Shares
8,614
Total Value
$720,039.95
Owned After
24,578.031
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Downing Cristal N | MRK | Chief Comm. & Public Afrs Ofcr | Nov 10, 2025 | Sell | $87.00 | 7,085 | $616,395.00 | 0 | |
| Williams David Michael | MRK | EVP,Chief Info&Digital Officer | Nov 3, 2025 | Sell | $83.59 | 8,614 | $720,039.95 | 24,578.031 |
Latest Merck & Company Inc. (new) News
MRK Breaking Stock News: Dive into MRK Ticker-Specific Updates for Smart Investing
Zacks
Pfizer's Cancer Drugs Deliver Growth Amid Competitive Pressure
📊
AI Sentiment
Positive
7/10
Investing.com
Vaccine stocks brace for shock waves at this week’s ACIP meeting
âž–
AI Sentiment
Neutral
4/10
Simply Wall St.
Has Merck’s Valuation Shifted After Key Pipeline Updates and an 18% Stock Jump?
📈
AI Sentiment
Highly Positive
8/10
PR Newswire
Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy
📈
AI Sentiment
Highly Positive
9/10
Investor's Business Daily
Stock Market Today: Indexes End Lower; Moderna Dives On FDA Memo; Synopsys, Nvidia Jump (Live Coverage)
📉
AI Sentiment
Negative
3/10
Compare MRK vs Leading Stocks
See how MRK stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MRK Merck & Company Inc. (new) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.